Clinical study COLCOT-T2D :
Clinical study COLCOT-T2D :Prevention of heart disease in people with type 2 diabetes
The FDA has approved colchicine for the prevention of cardiovascular events in individuals with a pre-existing heart condition, using data from the COLCOT study conducted by the Montreal Heart Institute with the MHICC. The COLCOT-T2D study will assess whether colchicine also works in primary prevention for type 2 diabetics who do not have coronary heart disease.
Click here to read the article in the Financial Post.